Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.

Song MK, Park BB, Uhm JE.

Int J Mol Sci. 2019 Oct 10;20(20). pii: E5010. doi: 10.3390/ijms20205010. Review.


Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

Song MK, Park BB, Uhm JE.

Int J Mol Sci. 2018 Mar 18;19(3). pii: E898. doi: 10.3390/ijms19030898. Review.


Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.

Baek KK, Kim JH, Uhm JE, Park SH, Lee J, Park JO, Park YS, Kang WK, Lim HY.

Oncology. 2011;80(3-4):167-74. doi: 10.1159/000327591. Epub 2011 Jun 24.


Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.


Analysis of prognostic factors of pediatric-type sarcomas in adult patients.

Ahn HK, Uhm JE, Lee J, Lim DH, Seo SW, Sung KS, Lee SJ, Lee DJ, Baek KK, Kim WS, Park JO.

Oncology. 2011;80(1-2):21-8. doi: 10.1159/000327222. Epub 2011 May 23.


Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes.

Lim T, Kim SJ, Kim K, Lee JI, Lim DH, Lee DJ, Baek KK, Lee HY, Han B, Uhm JE, Ko YH, Kim WS.

Ann Hematol. 2011 Dec;90(12):1391-8. doi: 10.1007/s00277-011-1225-0. Epub 2011 Apr 9.


Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH.

BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527.


Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.

Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K.

J Thorac Oncol. 2009 Sep;4(9):1136-43. doi: 10.1097/JTO.0b013e3181b270a7.


A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.

Kim HS, Park MJ, Uhm JE, Lee Y, Lee HY, Kang EM, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS.

Int J Colorectal Dis. 2009 Nov;24(11):1311-6. doi: 10.1007/s00384-009-0758-3. Epub 2009 Jul 17.


A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma.

Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, Lee JI, Nam DH, Park W, Lim do H, Kim SJ, Kim K, Ko YH, Kim WS.

Leuk Lymphoma. 2009 Jul;50(7):1110-8. doi: 10.1080/10428190902964776.


A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.

Ji SH, Lim DH, Yi SY, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK.

BMC Cancer. 2009 Apr 9;9:110. doi: 10.1186/1471-2407-9-110.


Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer.

Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K.

Cancer Chemother Pharmacol. 2009 Oct;64(5):917-24. doi: 10.1007/s00280-009-0943-7. Epub 2009 Feb 17.


Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH.

Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090.


The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.

Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7.


Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H.

Med Oncol. 2009;26(2):186-92. doi: 10.1007/s12032-008-9106-7. Epub 2008 Nov 6.


Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.

Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7.


A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.

Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY.

Cancer Chemother Pharmacol. 2009 Apr;63(5):929-35. doi: 10.1007/s00280-008-0817-4. Epub 2008 Aug 23.


Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".

Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS.

Ann Hematol. 2009 Feb;88(2):111-9. doi: 10.1007/s00277-008-0544-2. Epub 2008 Jul 22.


Prognostic factor analysis in patients with brain metastases from breast cancer: how can we improve the treatment outcomes?

Park BB, Uhm JE, Cho EY, Choi YL, Ji SH, Nam DH, Lee JI, Park W, Huh SJ, Park YH, Ahn JS, Im YH.

Cancer Chemother Pharmacol. 2009 Mar;63(4):627-33. doi: 10.1007/s00280-008-0779-6. Epub 2008 Jun 14.


Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.

Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, Lee SC, Hwang IG, Koh KC, Lee MH, Ahn JS, Kim WS, Jung CW, Kang WK.

Biol Blood Marrow Transplant. 2007 Apr;13(4):463-8.

Supplemental Content

Loading ...
Support Center